| 國立成功大學 |
2022 |
The Efficacy and Safety of Short-Term Tolvaptan Usage in Patients with Acute Decompensated Heart Failure
|
Lin, Y.-H.;Tsai, C.-H.;Chiang, Chiang C.-E.;Kuo, J.-Y.;Yin, W.-H.;Wen, M.-S.;Lo, P.-H.;Liu, P.-Y.;Lin, T.-H.;Chen, Z.-C.;Shyu, K.-G.;Hung, M.-J.;Hwang, J.-J.;Tseng, C.-D. |
| 國立成功大學 |
2022 |
Multicenter surveillance of antimicrobial susceptibilities and resistance mechanisms among Enterobacterales species and non-fermenting Gram-negative bacteria from different infection sources in Taiwan from 2016 to 2018
|
Jean, S.-S.;Lee, Y.-L.;Liu, P.-Y.;Lu, M.-C.;Ko, W.-C.;Hsueh, P.-R. |
| 臺大學術典藏 |
2021-12-22T03:54:04Z |
2017 Taiwan lipid guidelines for high risk patients
|
Li Y.-H.; Ueng K.-C.; JIANN-SHING JENG; Charng M.-J.; Lin T.-H.; Chien K.-L.; Wang C.-Y.; Chao T.-H.; Liu P.-Y.; Su C.-H.; Chien S.-C.; Liou C.-W.; Tang S.-C.; Lee C.-C.; Yu T.-Y.; Chen J.-W.; Wu C.-C.; Yeh H.-I.; The Writing Group of 2017 Taiwan Lipid Guidelines for High Risk Patients |
| 臺大學術典藏 |
2021-12-22T03:53:55Z |
Erratum: ‘Corrigendum to “2017 Taiwan lipid guidelines for high risk patients” [Journal of the Formosan Medical Association (2017) [217–248]’(S0929664616304302)(10.1016/j.jfma.2016.11.013)
|
Li Y.-H.; Ueng K.-C.; JIANN-SHING JENG; Charng M.-J.; Lin T.-H.; Chien K.-L.; Wang C.-Y.; Chao T.-H.; Liu P.-Y.; Su C.-H.; Chien S.-C.; Liou C.-W.; Tang S.-C.; Lee C.-C.; Yu T.-Y.; Chen J.-W.; Wu C.-C.; Yeh H.-I.; The Writing Group of 2017 Taiwan Lipid Guidelines for High Risk Patients |
| 臺大學術典藏 |
2021-12-02T05:41:24Z |
Clinical application of metagenomic next-generation sequencing in patients with hematologic malignancies suffering from sepsis
|
WANG-DA LIU; Yen T.-Y.; Liu P.-Y.; Wu U.-I.; Bhan P.; Li Y.-C.; Chi C.-H.; Sheng W.-H. |
| 臺大學術典藏 |
2021-09-27T05:32:41Z |
In vitro activity of cefiderocol, cefepime/enmetazobactam, cefepime/zidebactam, eravacycline, omadacycline, and other comparative agents against carbapenem-non-susceptible Pseudomonas aeruginosa and Acinetobacter baumannii isolates associated from bloodstream infection in Taiwan between 2018–2020
|
Liu P.-Y.; Ko W.-C.; Lee W.-S.; Lu P.-L.; Chen Y.-H.; Cheng S.-H.; Lu M.-C.; Lin C.-Y.; Wu T.-S.; Yen M.-Y.; Wang L.-S.; Liu C.-P.; Shao P.-L.; Lee Y.-L.; Shi Z.-Y.; Chen Y.-S.; Wang F.-D.; Tseng S.-H.; Lin C.-N.; Chen Y.-H.; WANG-HUEI SHENG; Lee C.-M.; Tang H.-J.; Hsueh P.-R. |
| 臺大學術典藏 |
2021-09-27T05:32:39Z |
Antimicrobial susceptibility of bacteremic vancomycin-resistant Enterococcus faecium to eravacycline, omadacycline, lipoglycopeptides, and other comparator antibiotics: Results from the 2019–2020 Nationwide Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART)
|
Tsai H.-Y.; Lee Y.-L.; Liu P.-Y.; Lu M.-C.; Shao P.-L.; Lu P.-L.; Cheng S.-H.; Ko W.-C.; Lin C.-Y.; Wu T.-S.; Yen M.-Y.; Wang L.-S.; Liu C.-P.; Lee W.-S.; Shi Z.-Y.; Chen Y.-S.; Wang F.-D.; Tseng S.-H.; Chen Y.-H.; WANG-HUEI SHENG; Lee C.-M.; Chen Y.-H.; Liao C.-H.; Hsueh P.-R. |
| 臺大學術典藏 |
2021-09-27T05:32:37Z |
National surveillance of antimicrobial susceptibilities to dalbavancin, telavancin, tedizolid, eravacycline, omadacycline and other comparator antibiotics and serotype distribution of invasive Streptococcus pneumoniae isolates in adults: results from the Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART) programme in 2017–2020
|
Chien Y.-C.; Lee Y.-L.; Liu P.-Y.; Lu M.-C.; Shao P.-L.; Lu P.-L.; Cheng S.-H.; Lin C.-Y.; Wu T.-S.; Yen M.-Y.; Wang L.-S.; Liu C.-P.; Lee W.-S.; Shi Z.-Y.; Chen Y.-S.; Wang F.-D.; Tseng S.-H.; Chen Y.-H.; WANG-HUEI SHENG; Lee C.-M.; Chen Y.-H.; Ko W.-C.; Hsueh P.-R. |
| 臺大學術典藏 |
2021-08-31T05:27:01Z |
Acute aortic regurgitation caused by spontaneous aortic valve rupture
|
LI-TAN YANG; Liu P.-Y.; Lee C.-H.; Kan C.-D.; Li Y.-H.; Tsai L.-M.; Tsai W.-C. |
| 臺大學術典藏 |
2021-08-31T05:27:00Z |
The AMBITIOUS study design and rationale: Ambulatory blood pressure in Taiwanese occupational healthcare staff
|
LI-TAN YANG; Chen P.-W.; Lin T.-H.; Chiang K.-H.; Shih C.-M.; Hsieh M.-C.; Tseng W.-K.; Yeh H.-I.; Liu P.-Y. |
